[Dose finding for bronchospasmolytic drugs in clinical practice (authors' transl)]

Area of Science:

• Pharmacology
• Clinical Research
• Drug Development

Context:

• Investigation of bronchospasmolytic agents requires robust methodologies.
• Provocation tests are crucial for evaluating drug efficacy and safety in both healthy volunteers and patient populations.
• Establishing clear selection criteria and defining the "ideal" patient profile are essential for reproducible study outcomes.

Purpose:

• To outline optimal methods for investigating bronchospasmolytic agents.
• To emphasize the significance of provocation tests and patient selection in pharmacological studies.
• To discuss the determination of dose-response and time-response relationships for both therapeutic effects and adverse events.

Summary:

• The paper details investigation methods, stressing the importance of provocation tests, selection criteria, and defining the "ideal" patient for studying bronchospasmolytic agents.
• It covers determining dose-response and time-response for effects and side-effects, discussing the correlation between clinical, animal, and pharmacokinetic data for inhaled agents.

Impact:

• Provides a framework for designing more effective clinical trials of bronchospasmolytic drugs.
• Improves understanding of drug-action relationships, aiding in the development of safer and more efficacious treatments for respiratory conditions.
• Highlights challenges in correlating pharmacological and pharmacokinetic data for inhaled medications, guiding future research directions.